Learning Objectives:

• Define various types of drug metabolizers in the pharmacogenomics phenotypes

• Describe fundamental concepts of pharmacogenomics outlined in this presentation

• Discuss clinical outcomes resulting from the implementation of pharmacogenomics panel testing

• Identify the impact of pharmacogenomics in the prescriber practice

Accreditation

Mayo Clinic College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Mayo Clinic College of Medicine designates this live activity for a maximum of  1.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Summary

As a provider accredited by ACCME, Mayo Clinic College of Medicine (Mayo School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities.  Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity.  Safeguards against commercial bias have been put in place.  Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation.  Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program who have disclosed…

No relevant financial relationship(s) with industry:

Planning Committee:
Dr. Jamie Newman – none                       

Dr. Neel Shah – none

Andy Herber PA-C – none

Kyle Satterblom, PA-C – none

Emily Sorensen, DNP, APRN, CNP – none

Abigail Meyers, PA-C – none

Liz Canan – none

Amy Van Hoof – none

Presenter - None

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:

None